CN1333044A - Wasting-thirst hypoglycemic preparation - Google Patents
Wasting-thirst hypoglycemic preparation Download PDFInfo
- Publication number
- CN1333044A CN1333044A CN 01103594 CN01103594A CN1333044A CN 1333044 A CN1333044 A CN 1333044A CN 01103594 CN01103594 CN 01103594 CN 01103594 A CN01103594 A CN 01103594A CN 1333044 A CN1333044 A CN 1333044A
- Authority
- CN
- China
- Prior art keywords
- radix
- gram
- thirst
- wasting
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- 230000002218 hypoglycaemic effect Effects 0.000 title claims description 37
- 239000003814 drug Substances 0.000 claims abstract description 40
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 28
- 241000208340 Araliaceae Species 0.000 claims abstract description 11
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 11
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 11
- 235000008434 ginseng Nutrition 0.000 claims abstract description 11
- 239000009636 Huang Qi Substances 0.000 claims description 12
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 9
- 241000237903 Hirudo Species 0.000 claims description 7
- 239000006187 pill Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 8
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 241000405414 Rehmannia Species 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract 1
- 241000207929 Scutellaria Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 235000021028 berry Nutrition 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 46
- 239000008280 blood Substances 0.000 description 46
- 230000000694 effects Effects 0.000 description 21
- 235000000346 sugar Nutrition 0.000 description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 16
- 239000008103 glucose Substances 0.000 description 16
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 14
- 229940079593 drug Drugs 0.000 description 12
- 210000003743 erythrocyte Anatomy 0.000 description 12
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 239000000600 sorbitol Substances 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 9
- 239000008899 fufang danshen Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000007830 nerve conduction Effects 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 5
- 230000004089 microcirculation Effects 0.000 description 5
- 210000000578 peripheral nerve Anatomy 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 206010017711 Gangrene Diseases 0.000 description 4
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 231100000216 vascular lesion Toxicity 0.000 description 3
- 102000016912 Aldehyde Reductase Human genes 0.000 description 2
- 108010053754 Aldehyde reductase Proteins 0.000 description 2
- 206010021703 Indifference Diseases 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010040026 Sensory disturbance Diseases 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241000294142 Vascellum Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 102000011759 adducin Human genes 0.000 description 1
- 108010076723 adducin Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000020880 diabetic diet Nutrition 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000007905 drug manufacturing Methods 0.000 description 1
- 208000019479 dysautonomia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000020925 non fasting Nutrition 0.000 description 1
- 230000004987 nonapoptotic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 208000018290 primary dysautonomia Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a Chinese medicine for curing diabetes -"Xiaokejiangtangbao". Said invention is a pure Chinese medicine granular preparation which is made of 14 Chinese medicinal materials of astragalus root, ginseng, dried/fresh rehmannia, schisandra berry, scutellaria root and others. The tests show that it possesses obvious therapeutic effect, and can effectively eliminate complication.
Description
A kind of pure Chinese medicinal preparation " wasting-thirst hypoglycemic preparation " for the treatment of diabetes.
The diabetes traditional Chinese medical science claims " diabetes ", is a kind of chronic incretion disease, also is the global cardiovascular and cerebrovascular disease that is only second to, the chronic metabolism disorder syndrome of easily disabling that tumor is afterwards common, because cause of disease complexity, complication is many, so be still the medical circle a great problem so far.Can only select hypoglycemic medicine routinely for use at present, as: glyburide, insoral, diabetes pill etc.Regrettably, these medicines are difficult to control or cure this disease, can't fundamentally cure fully.So pressing at present can blood sugar lowering, can prevent and treat the efficient alleviative medicine of concurrent thereupon peripheral nerve and vascular complication again, serve patient.Over the past thousands of years, Chinese medicine and pharmacy has accumulated numerous controls " phlegm-damp ", " wet resistance ", the clinical experience of " diabetes " and theory.Surplus " wasting-thirst hypoglycemic preparation " that filters out obvious curative effects according to Chinese medicine rationale and clinical practice experience.Make granule, be used for clinically, curative effect is outstanding, and hypoglycemic effect is obvious especially.
Therefore medicine of the present invention is to be the Chinese patent medicine that feedstock production forms with following pharmaceutical composition.
Radix Astragali 100-200 gram;
Radix Ginseng 100-200 gram;
Radix Rehmanniae 100-200 gram;
Fructus Schisandrae Chinensis 100-200 gram;
Radix Scutellariae 50-100 gram;
Rhizoma Coptidis 50-100 gram;
Radix Paeoniae Rubra 50-100 gram;
Radix Salviae Miltiorrhizae 50-100 gram;
Cortex Moutan 50-100 gram;
Radix Puerariae 50-100 gram;
Radix Scrophulariae 50-100 gram;
Hirudo 50-100 gram;
Radix Paeoniae Alba 50-100 gram;
Radix Ophiopogonis 50-100 restrains (weight portion).
The preferred weight proportioning of pharmaceutical composition of the present invention is:
The Radix Astragali 100; Radix Ginseng 100; The Radix Rehmanniae 100; Fructus Schisandrae Chinensis 100; Radix Scutellariae 50; Rhizoma Coptidis 50; Radix Paeoniae Rubra 50; Radix Salviae Miltiorrhizae 50; Cortex Moutan 50; Radix Puerariae 50; Radix Scrophulariae 50; The Radix Paeoniae Alba 50; Hirudo 50; Radix Ophiopogonis 50 (weight portion).
The Radix Astragali, Radix Ginseng, the Radix Rehmanniae, Fructus Schisandrae Chinensis are monarch drug in the side, and the Radix Paeoniae Alba, Radix Ophiopogonis, Radix Puerariae, Radix Salviae Miltiorrhizae are ministerial drug, Radix Scutellariae, and Rhizoma Coptidis is an adjuvant drug, other draft this side for messenger drug.The Radix Astragali, the Radix Rehmanniae, Radix Scrophulariae, Radix Ophiopogonis, Rhizoma Coptidis, Radix Puerariae, Radix Scutellariae have hypoglycemic activity in the side; Rhizoma Coptidis, Radix Scutellariae have effect for reducing blood fat; The Radix Astragali, Radix Salviae Miltiorrhizae can reduce blood viscosity; And the Radix Salviae Miltiorrhizae blood circulation promoting and blood stasis dispelling, but Radix Scutellariae, Radix Puerariae be anticoagulant again, microcirculation improvement, Rhizoma Coptidis, Radix Scutellariae, Radix Scrophulariae have heat-clearing and toxic substances removing, wherein Radix Ginseng has the effect of QI invigorating promoting the production of body fluid to quench thirst, modern pharmacological research proves: Radix Ginseng can promote the metabolism of human body, and enhancing body is the resistance of bad condition to external world; And blood sugar lowering, and strengthen the human body self immunologic function, impel the reparation of impaired B cell.But Radix Astragali tonifying QI to promote blood circulation, the enhancing human body immunity ability prevents that liver glycogen from reducing, expansible blood vessel improves blood enforcement non-viable non-apoptotic cell and rejuvenates.Can enhance metabolism the defense function of enhancing body nonspecific stimulation to Fructus Schisandrae Chinensis research explanation modern age, but blood sugar lowering, the Radix Rehmanniae, Radix Scrophulariae heat clearing away enriching yin and nourishing kidney, blood sugar lowering, Cortex Moutan, Radix Puerariae clearing away heat and promoting production of body fluid, blood circulation promoting and blood stasis dispelling, blood vessel dilating, microcirculation improvement, recovery islets of langerhans activity, blood sugar lowering, Rhizoma Coptidis blood fat reducing, the expansion peripheral vessel, promote beta Cell of islet regeneration and recover its function have and adjust congenital day after tomorrow of function, balance whole body yang blood and qi body fluid wonderful.The effect that all medicines share, too many levels is played " supplementing QI and nourishing YIN heat clearing away, activating blood circulation to dissipate blood stasis and dredge the collateral " altogether makes the gas nourishing YIN multiple, and stasis of blood heat-transformation is clear, and negative and positive are coordinated, and disease spontaneous recovery for the diabetes complicated peripheral nerve of treatment all kinds, vascular lesion, provides foundation.
From the treatment of animal experiment and clinical patient, can find out clearly that " Xue Shi wasting-thirst hypoglycemic preparation " square medicine has hypoglycemic effect really, be better than " diabetes pill, insoral ", the acquisition of this effect is like relevant with the activity that stimulates insulin secretion.Also have the reduction serum total cholesterol, TG improves HDL
-The content of C improves in the histiocyte important antioxidase system in the free radical scavenging system, the erythrocyte sod activity, antiplatelet aggregation lowers blood viscosity, plasma viscosity, thereby improved the small circulatory function of organ-tissue, increased the blood oxygen supply of tissue, accelerated nerve conduction velocity.Along with the state of an illness increases the weight of, type of deficiency of both QI and YIN and the type of deficiency of both QI and YIN blood stasis person erythrocyte sorbitol content of holding concurrently obviously raises gradually, after the medication in the erythrocyte minimizing of sorbitol aggregate amount and the improvement of diabetes nerve vascular lesion be proportionate.Results suggest, the diabetes state of an illness (companion is peripheral nerve not, the vascular complication and the no Blood stasis of holding concurrently), the quantizating index of the objective and feasible of weight are weighed in how much can be used as of erythrocyte sorbitol content.Blood glucose value does not have dependency before and after remarkable decline of " Xue Shi wasting-thirst hypoglycemic preparation " treatment back erythrocyte sorbitol content and the treatment, this just illustrates that " Xue Shi wasting-thirst hypoglycemic preparation " causes sorbitol content decline, not through blood glucose but through suppressing aldose reductase activity and realizing.Chinese scholars confirms already: the Radix Astragali, the Radix Paeoniae Alba, Radix Puerariae, Radix Scutellariae, Radix Rehmanniae, Radix Salviae Miltiorrhizae have the inhibition aldose reductase activity, suppress glycometabolic polyhydric alcohol activity, reduce sorbitol fructose and stop proteinic nonenzymatic glycosylation." Xue Shi wasting-thirst hypoglycemic preparation " can have good effect by the probability of stopping diabetes initiation chronic complicating diseases at many levels like this, safe and reliable, taking convenience can blood sugar lowering, can prevent the effect of chronic complicating diseases again, reduce the disability rate that causes death, clinical symptoms body card is significantly improved and is disappeared, and removes patient's misery, and general curative effect is better than diabetes pill, insoral, the excellent medicine of blood sugar lowering.The all medicine QI invigorating of we and the gas that do not stagnate, yin nourishing and do not grow is greasyly invigorated blood circulation and just do not hindered, and is cold and cool and do not decrease spleen, embodied the rule of treatment of " three types of diabetes is ruled together ", and it is clear that gas the moon must be answered stasis of blood heat-transformation, disease spontaneous recovery.
Pharmaceutical composition of the present invention can be prepared into any pharmaceutical preparation that is suitable for using clinically according to conventional formulation technology.For example: tablet, powder, pill, granule, capsule, oral liquid etc.
Pharmaceutical composition of the present invention can directly be made each patent medicine, also can extract respectively each combination of compositions, prepares patent medicine then, and these are all within protection scope of the present invention.
Process for preparing medicine of the present invention is:
1, selected crude drug: selected high-quality Chinese crude drug, to remove impurity, and differentiate and the run-of-the-mill check by pharmacopeia regulation, defective medical material such as of poor quality, as to go bad, damage by worms, go mouldy must not use.
2; processing: with the Radix Astragali; Radix Ginseng; the Radix Rehmanniae; Fructus Schisandrae Chinensis; Radix Scutellariae; Rhizoma Coptidis; Radix Paeoniae Rubra; Radix Salviae Miltiorrhizae; Cortex Moutan; Radix Puerariae; Radix Scrophulariae; the Radix Paeoniae Alba; Hirudo; Radix Ophiopogonis adds 8 times of water loggings or does not have powder 2～3cm; heating decocts 2 hours after-filtration; medicinal residues add 4 times of amounts of water; heating decocts for the second time again; filtered in 1 hour; the merging filtrate low-temperature evaporation; be concentrated into half amount of original volume, add 95% ethanol equivalent mixing and spend the night and make sedimentation, supernatant inclines; ethanol is reclaimed in distillation; revaporization concentrates, and puts cold place and precipitation is filtered fully in 24 hours, and the filtrate low-temperature evaporation is to dense shape (water content 20%); add an amount of excipient mixing; make soft material with 70% ethanol, move to granulation machine 12 orders and granulate, put in the baking oven dry again under the low temperature; remove than fine grained and make evenly, 15 grams are packed.
3, character " Xue Shi wasting-thirst hypoglycemic preparation " is a sepia, and the medical herbs abnormal smells from the patient is soluble in water.
Experimental study:
One, adopts 40 of white mice.Reagent adopts alloxan, and the time spent is mixed with 0.1% solution with normal saline.Instrument carries out with blood sugar detection instrument (glucose oxidase method).Hemorheology index detects with P80 type blood viscometer.The erythrocyte sod activity adopts ultraviolet spectrophotometer to measure.Insulin RIA medicine closes with SN-682B radioimmunity y
-Enumerator detects.
Two, control drug: insoral, glyburide, FUFANG DANSHEN PIAN.
Three, provided by the Drug Manufacturing Room of Chinese medicine scientific research institution by reagent thing " Xue Shi wasting-thirst hypoglycemic preparation ", every gram contains crude drug 2 grams, and per generations 15 restrain.
Test method:
One, with 40 of white mice, fasting 5 hours, tail vein injection 0.6% alloxan solution (60mg/kg).Allow white mice fasting 5 hours after two weeks again, blood is got in docking, surveys blood glucose value with the blood sugar detection instrument, and all non-fasting blood sugars are higher than 16.7mmoi/l and are successful A11 diabetes model Mus.Can include the diabetes test group in.Be divided into " Xue Shi wasting-thirst hypoglycemic preparation " treatment group at random, insoral, FUFANG DANSHEN PIAN matched group, every group of 20 diabetes model Mus.Do following processing outward for day general feeds for every group: 20 of treatment groups, 30 gram/kg/d.With gastric infusion; 20 of matched groups, 27 gram/kg/d, each organizes every Mus every day 1 time, continuous 30 days, surveyed blood glucose once in per 10 days, body weight once, each measuring blood needs fasting 5 hours (can't help drink), surveys administration in last hour.The routine number of rat tail end gangrene is respectively organized in record in the 20th day.Each group of measurement all around.24 hours amounts of drinking water of every Mus and twenty-four-hour urine amount.The 30th day broken end got blood and surveyed blood glucose, blood fat, erythrocyte sod activity.
Result and analysis
One, experimentation:
(1) " Xue Shi wasting-thirst hypoglycemic preparation " treatment group and insoral matched group all significantly reduce the blood glucose of diabetes rat, and medication was compared with matched group after 30 days, and significant difference is all arranged.
(2) " Xue Shi wasting-thirst hypoglycemic preparation " treatment group can significantly improve the serum insulin content of diabetes tests Mus, illustrate that the partly cause of blood sugar reducing function of " Xue Shi wasting-thirst hypoglycemic preparation " is relevant with stimulation insulin cell insulin secretion.
(3) " Xue Shi wasting-thirst hypoglycemic preparation " can significantly reduce serum triglycerides, improves the high-density protein cholesterol level, and insoral, FUFANG DANSHEN PIAN also can reduce serum triglycerides content, but no difference of science of statistics.
(4) " Xue Shi wasting-thirst hypoglycemic preparation " and insoral, FUFANG DANSHEN PIAN all can significantly reduce diabetes test Mus whole blood viscosity, plasma viscosity and packed cell volume.
(5) " Xue Shi wasting-thirst hypoglycemic preparation " all can significantly improve diabetes test Mus erythrocyte sod activity with insoral, and FUFANG DANSHEN PIAN does not have obvious influence.
(6) " Xue Shi wasting-thirst hypoglycemic preparation " can significantly reduce amount of drinking water and the urine amount of diabetes test Mus, and the insoral group also has effect but the indifference opposite sex.
(7) " Xue Shi wasting-thirst hypoglycemic preparation " can significantly reduce the incidence rate of diabetes tests Mus tail end gangrene, and insoral and FUFANG DANSHEN PIAN also can reduce the incidence rate of tail end gangrene but the indifference opposite sex.
Clinical research
One, the object of observation:
Belong to the secondary diabetes with peripheral nerve, vascular complication symptom, and sign person (companion's sensory disturbance, tendon reflex weakens, disappears, dysautonomia, the center, the total motor nerve conduction velocity of calf is unusual, refers to the toe cyanosis, skin ulcer, gangrene forms 100 examples: male 50 examples, women 50 examples.Be divided at random: 50 examples are organized in " Xue Shi wasting-thirst hypoglycemic preparation " treatment, 54.50 ± 10.2 years old mean age, average 7.9 ± 4.0 years of the course of disease; Matched group 50 examples, 55.2 ± 11.5 years old mean age.Average 7.5 ± 4.5 years of the course of disease.According to Ministry of Public Health bureau of drug administration " new drug (Chinese medicine) treatment diabete clinical research technological guidance principle ", be divided into " Xue Shi wasting-thirst hypoglycemic preparation " treatment with the measurement of Chinese medicine typing standard and organize 50 examples, the treatment matched group adopts " insoral, FUFANG DANSHEN PIAN " 50 examples.
Two, observation index
1. symptom and sign, per 2 week record once, comprehensively weigh increase and decrease, improve, disappear.
2. fasting glucose.
Three, observational technique
Treatment is organized in taking medicine before meal with " Xue Shi wasting-thirst hypoglycemic preparation " every day 3 times, each 1 bag of 15 gram.
Matched group in taking medicine before meal with hypoglycemic medicine as insoral, FUFANG DANSHEN PIAN.Be for 8 weeks the course of treatment.Two groups of observed patients are all at inactive hypoglycemic medicine after 1 week, do 100 gram bread meal tests, survey and reach 1 hour after the meal, 2 hours, 3 hours blood glucose, glucose in urine, erythrocyte sorbitol content on an empty stomach, electromyogram (nerve conduction velocity), examination of nail fold microcirculation is all respectively carried out once before and after treatment.Careful understanding treatment of the 8th week symptom, the sign situation of change.Advance diabetic diet (heat 1500-11800Kcal every day) during two groups of patient and suspend other blood sugar lowering medicament for expanding vascellum.
Four, criterion of therapeutical effect: the clinical efficacy judgement is set about from weighing the clinical symptoms therapeutic effect.
1. produce effects: clinical symptom disappearance, the total motor nerve conduction velocity of center calf recovers normal; Microcirculation has improvement, and between total mark decline 2-4 divided, the erythrocyte sorbitol content returned to normal level substantially.
2. effective: clinical symptoms is obviously improved, and center, the total motor nerve conduction velocity of calf obviously speed, and microcirculation has improvement, and total mark descended more than 2 minutes, and the erythrocyte sorbitol content descends also not obvious.
3. invalid: no significant change before and after the treatment.The 8th week write down once.
Five, result and analysis
(1) " Xue Shi wasting-thirst hypoglycemic preparation " treatment group obvious effective rate 82%, and total effective rate 94.5% obviously is better than matched group (38% and 52%).
(2) " Xue Shi wasting-thirst hypoglycemic preparation " treatment 8 week backs are to diabetics, and center, calf are total, motor nerve conduction velocity obviously speeds, and before the treatment significant differences are arranged.
(3) after 8 weeks of " Xue Shi wasting-thirst hypoglycemic preparation " treatment improvement of diabetics peripheral nerve vascular lesion symptom body card or disappearance rate obviously are better than matched group.
(4) form integration after 8 weeks of " Xue Shi wasting-thirst hypoglycemic preparation " treatment, the fluidised form integration, total mark all significantly descends, and amplitude is greater than matched group.
(5) " Xue Shi wasting-thirst hypoglycemic preparation " all has decline with treatment of control group 8 all backs blood sugar levels, and the matched group fall is slower than the precious treatment group of blood sugar lowering.
(6) " Xue Shi wasting-thirst hypoglycemic preparation " treatment group and treatment of control group are after 8 weeks, and " blood sugar lowering treasured " treatment group erythrocyte sorbitol content significantly descends before the treatment, and its amplitude and matched group have evident difference.
Case one: Zhao * *, 52 years old, the worker, dry mouth and throat is felt in first visit in May nineteen ninety-five nearly January, the dysphoria with smothery sensation dreaminess is had a dizzy spell, soreness of the waist and knees, constipation with dry stool, the red tongue tongue is few, and thready and rapid pulse is fat, has a blood test and presses higher 20/12KP
2, glucose in urine +++, blood glucose 10.9mmol/L, cholesterol 7.6mmol/L, triglyceride 3.0mml/L examines and is type-II diabetes, traditional Chinese medical science diabetes, YIN-deficiency type, lung dryness of the stomach heat, the hepatic and renal YIN deficiency, control with nourishing YIN to relieve dryness, nourishing the liver and kidney is with " Xue Shi wasting-thirst hypoglycemic preparation " each 1 bag 15 grams, days 3 times are oral, 2 months transference cures of taking medicine, and defence obeys a course of treatment again, the sugared 5.8mmol/L that has a blood test, glucose in urine () is followed up a case by regular visits to and was not seen recurrence in 5 years.
Case two, strain * *, 58 years old, trade, on October 8th, 1997 went to a doctor, suffered from diabetes 3 years, clothes diabetes pill, insoral treatment, state of an illness shakiness, blood glucose fluctuation between 10.9～15.1mmol/L, glucose in urine+extremely +++between, the state of an illness increases the weight of and goes to a doctor spiritlessness and weakness recently, the spontaneous perspiration of breathing hard, dry mouth and throat, thirsty not polydipsia, food is not known flavor, dizzy tinnitus, soreness of the waist and knees is become thin, turbid urine, the pool after stool is done before sb. else, light red tongue, tongue is white, thready and weak pulse.Sugar has urine examined ++ ++, blood glucose 15.9mmol/L, cholesterol 7.5mml/L, card belongs to deficiency of both QI and YIN, spleen is suffered from a deficiency of the kidney.Method of treatment gives " wasting-thirst hypoglycemic preparation " clothes one course of treatment, and symptom is clearly better, and continue and obey 2 courses of treatment, the sugar that has urine examined (one), blood glucose 7.1mmol/L, cholesterol 5.8mml/L, advising continues obeyed for 1 course of treatment to consolidate curative effect.
Claims (3)
- One, a kind of pure Chinese medicinal preparation " Xue Shi wasting-thirst hypoglycemic preparation " for the treatment of diabetes, it is characterized in that with the Radix Astragali, Radix Ginseng, the Radix Rehmanniae, Fructus Schisandrae Chinensis, Radix Scutellariae, Rhizoma Coptidis, Radix Paeoniae Rubra, Radix Salviae Miltiorrhizae, Cortex Moutan, Radix Puerariae, Radix Scrophulariae, the Radix Paeoniae Alba, Hirudo, Radix Ophiopogonis the medicament that is prepared from according to following proportioning:Radix Astragali 100-200 gram;Radix Ginseng 100-200 gram;Radix Rehmanniae 100-200 gram;Fructus Schisandrae Chinensis 100-200 gram;Radix Scutellariae 50-100 gram;Rhizoma Coptidis 50-100 gram;Radix Paeoniae Rubra 50-100 gram;Radix Salviae Miltiorrhizae 50-100 gram;Cortex Moutan 50-100 gram;Radix Puerariae 50-100 gram;Radix Scrophulariae 50-100 gram;Hirudo 50-100 gram;Radix Paeoniae Alba 50-100 gram;Radix Ophiopogonis 50-100 restrains (weight portion).
- Two, Chinese medicine according to claim 1 is characterized in that the Radix Astragali and Radix Ginseng, the Radix Rehmanniae and Fructus Schisandrae Chinensis, and Radix Scutellariae and Rhizoma Coptidis, Radix Paeoniae Rubra and Radix Salviae Miltiorrhizae, Cortex Moutan and Radix Puerariae, unit participates in the Radix Paeoniae Alba, and the proportioning of Hirudo and Radix Ophiopogonis is: the Radix Astragali 100; Radix Ginseng 100; The Radix Rehmanniae 100; Fructus Schisandrae Chinensis 100; Radix Scutellariae 50; Rhizoma Coptidis 50; Radix Paeoniae Rubra 50; Radix Salviae Miltiorrhizae 50; Cortex Moutan 50; Radix Puerariae 50; Radix Scrophulariae 50; The Radix Paeoniae Alba 50; Hirudo 50; Radix Ophiopogonis 50 (weight portion).
- Three, according to the Chinese medicine of claim 1 or 14, the dosage form that it is characterized in that this medicine is any of tablet, powder, pill, capsule, granule, oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01103594 CN1333044A (en) | 2001-03-10 | 2001-03-10 | Wasting-thirst hypoglycemic preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01103594 CN1333044A (en) | 2001-03-10 | 2001-03-10 | Wasting-thirst hypoglycemic preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1333044A true CN1333044A (en) | 2002-01-30 |
Family
ID=4653348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01103594 Pending CN1333044A (en) | 2001-03-10 | 2001-03-10 | Wasting-thirst hypoglycemic preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1333044A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101361821B (en) * | 2008-10-10 | 2012-11-14 | 北京中医药大学 | Medicine combination for treating diabetic peripheral neuropathy and preparation method thereof |
| CN104013807A (en) * | 2014-06-25 | 2014-09-03 | 石岩 | Preparation method of Chinese patent medicine particles for treating diabetes |
| CN104277958A (en) * | 2014-10-30 | 2015-01-14 | 范鹏琳 | Health wine for reducing blood sugar level |
| CN105998611A (en) * | 2016-05-27 | 2016-10-12 | 湖南中医药大学 | Medicinal composition as well as preparation method and applications thereof |
| CN107802789A (en) * | 2017-11-24 | 2018-03-16 | 海城市中医院 | A kind of Chinese medicine preparation and its instructions of taking for preventing and treating diabetes |
-
2001
- 2001-03-10 CN CN 01103594 patent/CN1333044A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101361821B (en) * | 2008-10-10 | 2012-11-14 | 北京中医药大学 | Medicine combination for treating diabetic peripheral neuropathy and preparation method thereof |
| CN104013807A (en) * | 2014-06-25 | 2014-09-03 | 石岩 | Preparation method of Chinese patent medicine particles for treating diabetes |
| CN104013807B (en) * | 2014-06-25 | 2017-08-25 | 石岩 | A kind of preparation method for treating Chinese Patent Drugs for Diabetes particle |
| CN104277958A (en) * | 2014-10-30 | 2015-01-14 | 范鹏琳 | Health wine for reducing blood sugar level |
| CN105998611A (en) * | 2016-05-27 | 2016-10-12 | 湖南中医药大学 | Medicinal composition as well as preparation method and applications thereof |
| CN105998611B (en) * | 2016-05-27 | 2019-06-18 | 湖南中医药大学 | A kind of pharmaceutical composition and preparation method and application |
| CN107802789A (en) * | 2017-11-24 | 2018-03-16 | 海城市中医院 | A kind of Chinese medicine preparation and its instructions of taking for preventing and treating diabetes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101596230B (en) | Medicinal composition for treating hepatopathy | |
| CN104107324A (en) | Traditional Chinese medicine compound preparation for treating type II diabetes mellitus and preparation method of traditional Chinese medicine compound preparation | |
| CN100493572C (en) | Composition of medication for treating diabetes | |
| CN1558768A (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
| CN102626468A (en) | Traditional Chinese medicine combination for treating hepatitis B and preparing method and application thereof | |
| CN102631526B (en) | Chinese medicinal composition for treating diabetes mellitus | |
| CN102462834A (en) | Medicinal composition for controlling blood sugar of diabetic | |
| CN1471845A (en) | Healthy food with glossy and rhizoma as main material and preparing method thereof | |
| CN1683001A (en) | Chinese medicine for treating gout | |
| CN1333044A (en) | Wasting-thirst hypoglycemic preparation | |
| CN102940800A (en) | Traditional Chinese medicine for treating diabetes | |
| CN103211996B (en) | Preparation method of traditional Chinese medicine for treating diabetes mellitus | |
| CN102657730A (en) | Rhodiola rosea buccal preparations for resisting altitude reaction | |
| CN106309729B (en) | A kind of Chinese medicine composition adjusting chronic hepatitis immune function | |
| CN1883582A (en) | Pharmaceutical composition for treating liver disease and method for preparing same | |
| CN103230552B (en) | Traditional Chinese medicine for treating diabetes mellitus | |
| CN100471488C (en) | Chinese medicine composition for transquilizing, warming Yang, benefiting Qi and nourishing heart and its prepn | |
| CN101618156A (en) | Medicine composition for treating hepatitis B and preparation method thereof | |
| CN101642485B (en) | Application of medical composition containing astragalus root in preparing medicine for treating leucopenia and Henoch-Schonlein Purpura | |
| CN1943718B (en) | A Chinese traditional medicinal composition and its preparation method | |
| CN116832083B (en) | Preparation process and application of traditional Chinese medicine tea beverage composition capable of preventing early glycolipid metabolic disorder | |
| CN1401371A (en) | 'Shenhuaxiaokecha' tea and preparing method thereof | |
| CN1076622C (en) | Chinese medicine for curing nephritis | |
| CN1424063A (en) | Oral medicinal composition for treating diabetes | |
| CN1602949A (en) | Compound capsule for treating meridian wind-phlegm stasis in stroke and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| AD01 | Patent right deemed abandoned | ||
| C20 | Patent right or utility model deemed to be abandoned or is abandoned |